. Further investigations to discover novel therapeutic targets or optimize the current drug targets are critical for the success of this cotargeting strategy.
This newly published study has several strengths. blockade. Furthermore, the study includes both mechanistic and biomarker studies, which conclude that Gal-3 not only is a mediator for AKI-induced cardiac injury but also may be a biomarker for AKI severity.
It is unclear what is the deleterious signal transmitted to the bone marrow from the injured kidney.
Therefore, it will be of interest to investigate the hormonal or neural signals generated by the kidney and the causal relationship between the unknown signals and bone marrow Gal-3 formation. Furthermore, the authors did not mention the effect of modified citrus pectin or Gal-3 KO on cardiovascular hemodynamics such as blood pressure in the mice.
This key information may further contribute to the cardiac improvement observed in the current study and should be studied. Additionally, future studies to investigate renin-angiotensin-aldosterone system modulation by Gal-3 suppression will be important because studies have previously documented the critical role of the system in inflammation and cardiac injury, with AKI initiation (2,10).
Gal-3 inhibition exerted potent cardiac protective effects in 2 kidney injury models but did not improve renal function or reduce renal structural abnormalities, which consequently may limit its use for AKI prevention or treatment itself. Thus, optimizing the dose, potency, and organ selectivity of a Gal-3 inhibitor to improve renal function such as increasing glomerular filtration rate or urine output is critical for the future development of a Gal-3 blockade strategy for AKI management. Additionally, from a therapeutic perspective, the authors may want to consider investigating disease models that focus on myocardial therapeutics with the use of Gal-3 inhibition.
Future directions also include validating the therapeutic potential of Gal-3 inhibition in a large-animal model such as canines or porcines, which constitute a higher functional similarity and genetic homogeneity with humans.
Biomarker studies measuring plasma Gal-3 at admission (in addition to discharge) for critically ill patients may also help to identify patients who will later develop AKI. Additionally, given the distribution of Gal-3 in renal tubules and macrophages, it will be interesting to evaluate urinary Gal-3 levels in AKI patients. Effective preventive strategies and interventions can then be used to treat these patients at 
